Search

Your search keyword '"Weltman M."' showing total 300 results

Search Constraints

Start Over You searched for: Author "Weltman M." Remove constraint Author: "Weltman M."
300 results on '"Weltman M."'

Search Results

1. Global multi-stakeholder endorsement of the MAFLD definition

2. Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort.

4. Management, outcomes and survival of an Australian IgG4-SC cohort: The MOSAIC study.

5. Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up.

10. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma

11. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients with Difficult to Cure Characteristics.

12. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients with Difficult to Cure Characteristics

13. Management, outcomes and survival of an Australian IgG4-SC cohort: The MOSAIC study

19. Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics.

20. Management, outcomes and survival of an Australian IgG4-sclerosing cholangitis cohort: The mosaic study.

21. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study

35. Efficacy and safety of sofosbuvir, velpatasvir, and voxilaprevir in NS5A-experienced patients with advanced liver disease or prior liver transplantation: The first Australian real-world experience.

36. Management, outcomes, and survival of an Australian IgG4-sclerosing cholangitis cohort: The MOSAIC study.

37. High rates of sustained virological response at 12 weeks in a real-world hospital-based cohort of direct-acting antiviral-treated patients with hepatitis C virus (HCV): The observational, prospective epidemiological registry in Australia of HCV (OPERA-C).

38. Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels

40. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

42. Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir +/- ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.

43. Response to mycophenolate mofetil in patients with autoimmune hepatitis who fail standard therapy is predicted by serum gammaglobulin levels but not by cirrhosis.

44. Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy.

45. NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double Blind Placebo Controlled Trial

46. Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study

47. IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis

48. Cannabidiol in the management of in-patient cannabis withdrawal: Clinical case series

49. O13 Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study

50. Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study

Catalog

Books, media, physical & digital resources